Marinomed Biotech AG specializes in the development of innovative products based on its IP protected technology platforms Marinosolv® and Carragelose®. Marinosolv® technology significantly increases the solubility and bioavailability of highly hydrophobic small molecular weight compounds or peptides hardly soluble in water. Marinomed has successfully validated the technology by improving established APIs in allergology and ophthalmology. Flutisolv (solubilised fluticasone) and Tacrosolv (solubilised tacrolimus) are available for out-licensing and further clinical co-developments. The technology platform Carragelose® comprises innovative patent protected virus-blocking products targeting respiratory viral infections. It is used in six different products sold globally via partners.

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Primary business activity


Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy

9-11 November 2021

Book a meeting
View Our Exhibitor Profile

Contact information




View All Contact Info